diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM12900diaendo-12900Research ArticleОбзорыReviewВзаимосвязь тяжелого острого респираторного синдрома, вызванного вирусом SARS-CoV-2, и сахарного диабета (обзор литературы)Relationship between severe acute respiratory syndrome coronavirus 2 and diabetes mellitus (review)https://orcid.org/0000-0002-7255-2088АртыкбаеваГ. М.ArtykbaevaG. M.

Артыкбаева Гульнора Мухамедовна – кандидат биологических наук, старший научный сотрудник; Scopus Author ID: 6506335901.

100174, Ташкент, Студенческий городок, д. 174

Gulnora M. Artykbaeva - PhD in Biology, senior research associate; Scopus Author ID: 6506335901.

174 Student campus, 100174 Tashkent

gulnoraart@mail.ruhttps://orcid.org/0000-0002-3272-3057СаатовТ. С.SaatovT. S.

Саатов Талат Саатович - докор биологических наук, профессор, академик АН РУз; Scopus Author ID: 7003376846; Researcher ID: U-2260-2017.

Ташкент

Talat S. Saatov - PhD in Biology, Professor, Academician of Sciences of the Republic of Uzbekistan; Scopus Author ID: 7003376846.

Tashkent

Saatovtalat4@gmail.comИнститут биофизики и биохимии, Национальный университет Узбекистана им. М. УлугбекаУзбекистанInstitute of biophysics and biochemistry, National University of Uzbekistan named after Mirzo UlugbekUzbekistan2023100220232616674Copyright © Артыкбаева Г.М., Саатов Т.С., 20232023Артыкбаева Г.М., Саатов Т.С.Artykbaeva G.M., Saatov T.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/12900

Инфекции, вызванные коронавирусом SARS-CoV-2, отягощаются сопутствующими патологиями, такими как гипертония, сахарный диабет (СД), сердечно-сосудистые заболевания. Высокий уровень глюкозы в крови снижает иммунитет и увеличивает репликацию SARS-CoV-2. Исход COVID-19 осложняется при наличии СД. Проникновение SARS-CoV-2 в клетку-хозяина происходит путем связывания с ангиотензинпревращающим ферментом 2. Инфекция COVID-19, стимулируя иммунные реакции, вызывает цитокиновый шторм и может привести к летальному исходу у пациентов с СД.

Последние лабораторные исследования показали, что одним из главных последствий у 14% пациентов, перенесших коронавирусную инфекцию, становится развитие СД 1 и 2 типов. Так, у 2% из этих пациентов диабет начал прогрессировать из-за коронавируса. У остальных он дебютировал как прямое и негативное последствие болезни. Гипергликемия приводит к образованию белковых молекул, называемых конечными продуктами гликирования (AGEs). AGEs и их рецепторы (RAGE) играют важную роль в вирусной инвазии в клетки хозяина. Поэтому для достижения оптимального исхода и снижения смертности необходим более жесткий контроль глюкозы. Целенаправленное воздействие на ось RAGE обеспечит лучший контроль течения COVID-19. Данный обзор проясняет молекулярный механизм обострения патофизиологии у пациентов с инфекцией COVID-19, ассоциированной с СД.

Infections caused by SARE-CoV-2 are complicated with the concurrent pathologies, to name hypertension, diabetes mellitus and cardiovascular diseases. High level of glucose in blood weakens the immunity and increase the SARS-CoV-2 replication. Diabetes mellitus aggravates the COVID-19 outcome. The intrusion of SARS-CoV-2 into a host-cell occurs by means of its association with the angiotensin-converting enzyme-2 (ACE 2). Stimulating immune responses the COVID-19 infection causes the cytokine storm, and may result in the lethal outcome in the diabetics.

Recent laboratory studies demonstrated that the type1 and type2 diabetes mellitus is the main consequence in 14% of the patients after corona infection. Thus, in 2% of 14% diabetes started progressing due to the corona virus. In the other, diabetes debut occurred as the direct and negative consequence of the disease. Hyperglycemia results in the formation of protein molecules known as the advanced glycation end products (AGEs). The AGEs and their receptors (RAGE) are of high significance in the host-cell’s virus invasion. Consequently, more strict glucose control is necessary for optimal outcome and reduction in mortality. The better control for the COVID-19 course can be provided by the targeted effect on the RAGE axis. The review helps elucidate the molecular mechanism underlying the exacerbation of pathophysiology in the diabetic COVID-19 patients.

SARS-CoV-2сахарный диабетангиотензинпревращающий ферментцитокиновый штормрецепторы конечных продуктов гликированияSARS-CoV-2diabetes mellitusangiotensin-converting enzymea cytokine stormadvanced glycation end product receptorsРабота выполнена по инициативе авторов без привлечения финансовых средствReferencesSarkar S, Das D, Borsingh Wann S, et al. Is diabetes mellitus a wrongdoer to COVID-19 severity? Diabetes Res Clin Pract. 2021;178(4):108936. doi: https://doi.org/10.1016/j.diabres.2021.108936Sarkar S, Das D, Borsingh Wann S, et al. Is diabetes mellitus a wrongdoer to COVID-19 severity? Diabetes Res Clin Pract. 2021;178(4):108936. doi: https://doi.org/10.1016/j.diabres.2021.108936Yang JK, Feng Y, Yuan MY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006;23(6):623-628. doi: https://doi.org/10.1111/j.1464-5491.2006.01861.xYang JK, Feng Y, Yuan MY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006;23(6):623-628. doi: https://doi.org/10.1111/j.1464-5491.2006.01861.xBanik GR, Alqahtani AS, Booy R, Rashid H. Risk factors for severity and mortality in patients with MERS-CoV: Analysis of publicly available data from Saudi Arabia. Virol Sin. 2016;31(1):81-84. doi: https://doi.org/10.1007/s12250-015-3679-zBanik GR, Alqahtani AS, Booy R, Rashid H. Risk factors for severity and mortality in patients with MERS-CoV: Analysis of publicly available data from Saudi Arabia. Virol Sin. 2016;31(1):81-84. doi: https://doi.org/10.1007/s12250-015-3679-zZhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi: https://doi.org/10.1016/S0140-6736(20)30566-3Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi: https://doi.org/10.1016/S0140-6736(20)30566-3Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574. doi: https://doi.org/10.1001/jama.2020.5394Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574. doi: https://doi.org/10.1001/jama.2020.5394Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221-224. doi: https://doi.org/10.21203/rs.2.24749/v1Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221-224. doi: https://doi.org/10.21203/rs.2.24749/v1Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181:271–80. doi: https://doi.org/10.1016/j.cell.2020.02.052Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181:271–80. doi: https://doi.org/10.1016/j.cell.2020.02.052Zhou L, Niu Z, Jiang X, et al. Systemic analysis of tissue cells potentially vulnerable to Sars-Cov-2 infection by the protein-proofed Single-Cell Rna Profiling of Ace2, Tmprss2 and furin proteases. SSRN Electron J. 2020. doi: https://doi.org/10.2139/ssrn.3589839Zhou L, Niu Z, Jiang X, et al. Systemic analysis of tissue cells potentially vulnerable to Sars-Cov-2 infection by the protein-proofed Single-Cell Rna Profiling of Ace2, Tmprss2 and furin proteases. SSRN Electron J. 2020. doi: https://doi.org/10.2139/ssrn.3589839Batlle D, Jose Soler M, Ye M. ACE2 and Diabetes: ACE of ACEs? Diabetes. 2010;59(12):2994-2996. doi: https://doi.org/10.2337/db10-1205Batlle D, Jose Soler M, Ye M. ACE2 and Diabetes: ACE of ACEs? Diabetes. 2010;59(12):2994-2996. doi: https://doi.org/10.2337/db10-1205Mizuiri S, Hemmi H, Arita M, et al. Expression of ACE and ACE2 in individuals with diabetic Kidney disease and healthy controls. Am J Kidney Dis. 2008;51(4):613-623. doi: https://doi.org/10.1053/j.ajkd.2007.11.022Mizuiri S, Hemmi H, Arita M, et al. Expression of ACE and ACE2 in individuals with diabetic Kidney disease and healthy controls. Am J Kidney Dis. 2008;51(4):613-623. doi: https://doi.org/10.1053/j.ajkd.2007.11.022Pal R, Bhansali A. COVID-19, diabetes mellitus and ACE2: The conundrum. Diabetes Res Clin Pract. 2020;(162):108132. doi: https://doi.org/10.1016/j.diabres.2020.108132Pal R, Bhansali A. COVID-19, diabetes mellitus and ACE2: The conundrum. Diabetes Res Clin Pract. 2020;(162):108132. doi: https://doi.org/10.1016/j.diabres.2020.108132Wijnant SRA, Jacobs M, Van Eeckhoutte HP, et al. Expression of ACE2, the SARS-CoV-2 receptor, in lung tissue of patients with type 2 diabetes. Diabetes. 2020;69(12):2691-2699. doi: https://doi.org/10.2337/db20-0669Wijnant SRA, Jacobs M, Van Eeckhoutte HP, et al. Expression of ACE2, the SARS-CoV-2 receptor, in lung tissue of patients with type 2 diabetes. Diabetes. 2020;69(12):2691-2699. doi: https://doi.org/10.2337/db20-0669Sukumaran V, Tsuchimochi H, Tatsumi E, et al. Azilsartan ameliorates diabetic cardiomyopathy in young db/db mice through the modulation of ACE-2/ANG 1–7/Mas receptor cascade. Biochem Pharmacol. 2017;(144):90-99. doi: https://doi.org/10.1016/j.bcp.2017.07.022Sukumaran V, Tsuchimochi H, Tatsumi E, et al. Azilsartan ameliorates diabetic cardiomyopathy in young db/db mice through the modulation of ACE-2/ANG 1–7/Mas receptor cascade. Biochem Pharmacol. 2017;(144):90-99. doi: https://doi.org/10.1016/j.bcp.2017.07.022Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. doi: https://doi.org/10.1016/S2213-2600(20)30116-8Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. doi: https://doi.org/10.1016/S2213-2600(20)30116-8Reynolds HR, Adhikari S, Pulgarin C, et al. Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;382(25):2441-2448. doi: https://doi.org/10.1056/NEJMoa2008975Reynolds HR, Adhikari S, Pulgarin C, et al. Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;382(25):2441-2448. doi: https://doi.org/10.1056/NEJMoa2008975Cohen JB, Hanff TC, William P, et al. Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021;9(3):275-284. doi: https://doi.org/10.1016/S2213-2600(20)30558-0Cohen JB, Hanff TC, William P, et al. Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021;9(3):275-284. doi: https://doi.org/10.1016/S2213-2600(20)30558-0Fignani D, Licata G, Brusco N, et al. SARS-CoV-2 receptor angiotensin i-converting enzyme type 2 (ACE2) is expressed in human pancreatic β-Cells and in the human pancreas microvasculature. Front Endocrinol (Lausanne). 2020;(11):596898. doi: https://doi.org/10.3389/fendo.2020.596898Fignani D, Licata G, Brusco N, et al. SARS-CoV-2 receptor angiotensin i-converting enzyme type 2 (ACE2) is expressed in human pancreatic β-Cells and in the human pancreas microvasculature. Front Endocrinol (Lausanne). 2020;(11):596898. doi: https://doi.org/10.3389/fendo.2020.596898Kusmartseva I, Wu W, Syed F, et al. Expression of SARS-CoV-2 entry factors in the pancreas of normal organ donors and Individuals with COVID-19. Cell Metab. 2020;32(6):1041-1051.e6. doi: https://doi.org/10.1016/j.cmet.2020.11.005Kusmartseva I, Wu W, Syed F, et al. Expression of SARS-CoV-2 entry factors in the pancreas of normal organ donors and Individuals with COVID-19. Cell Metab. 2020;32(6):1041-1051.e6. doi: https://doi.org/10.1016/j.cmet.2020.11.005Yang J-K, Lin S-S, Ji X-J, Guo L-M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193-199. doi: https://doi.org/10.1007/s00592-009-0109-4Yang J-K, Lin S-S, Ji X-J, Guo L-M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193-199. doi: https://doi.org/10.1007/s00592-009-0109-4Sathish T, Kapoor N, Cao Y, Tapp RJ, Zimmet P. Proportion of newly diagnosed diabetes in COVID‐19 patients: A systematic review and meta‐analysis. Diabetes, Obes Metab. 2021;23(3):870-874. doi: https://doi.org/10.1111/dom.14269Sathish T, Kapoor N, Cao Y, Tapp RJ, Zimmet P. Proportion of newly diagnosed diabetes in COVID‐19 patients: A systematic review and meta‐analysis. Diabetes, Obes Metab. 2021;23(3):870-874. doi: https://doi.org/10.1111/dom.14269Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID‐19. Diabetes Metab Res Rev. 2020;36(7):e3319. doi: https://doi.org/10.1002/dmrr.3319Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID‐19. Diabetes Metab Res Rev. 2020;36(7):e3319. doi: https://doi.org/10.1002/dmrr.3319Wu L, Girgis CM, Cheung NW. COVID‐19 and diabetes: Insulin requirements parallel illness severity in critically unwell patients. Clin Endocrinol (Oxf). 2020;93(4):390-393. doi: https://doi.org/10.1111/cen.14288Wu L, Girgis CM, Cheung NW. COVID‐19 and diabetes: Insulin requirements parallel illness severity in critically unwell patients. Clin Endocrinol (Oxf). 2020;93(4):390-393. doi: https://doi.org/10.1111/cen.14288Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98-107. doi: https://doi.org/10.1038/nri2925Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98-107. doi: https://doi.org/10.1038/nri2925Tay MZ, Poh CM, Rènia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363-374. doi: https://doi.org/10.1038/s41577-020-0311-8Tay MZ, Poh CM, Rènia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363-374. doi: https://doi.org/10.1038/s41577-020-0311-8Guo Y-R, Cao Q-D, Hong Z-S, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020;7(1):11. doi: https://doi.org/10.1186/s40779-020-00240-0Guo Y-R, Cao Q-D, Hong Z-S, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020;7(1):11. doi: https://doi.org/10.1186/s40779-020-00240-0Zhang C, Wu Z, Li J-W, et al. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954. doi: https://doi.org/10.1016/j.ijantimicag.2020.105954Zhang C, Wu Z, Li J-W, et al. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954. doi: https://doi.org/10.1016/j.ijantimicag.2020.105954Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-1099. doi: https://doi.org/10.1111/jth.14817Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-1099. doi: https://doi.org/10.1111/jth.14817Zhou P, Tachedjian M, Wynne JW, et al. Contraction of the type I IFN locus and unusual constitutive expression of IFN-α in bats. Proc Natl Acad Sci. 2016;113(10):2696-2701. doi: https://doi.org/10.1073/pnas.1518240113Zhou P, Tachedjian M, Wynne JW, et al. Contraction of the type I IFN locus and unusual constitutive expression of IFN-α in bats. Proc Natl Acad Sci. 2016;113(10):2696-2701. doi: https://doi.org/10.1073/pnas.1518240113Ahn M, Anderson DE, Zhang Q, et al. Dampened NLRP3-mediated inflammation in bats and implications for a special viral reservoir host. Nat Microbiol. 2019;4(5):789-799. doi: https://doi.org/10.1038/s41564-019-0371-3Ahn M, Anderson DE, Zhang Q, et al. Dampened NLRP3-mediated inflammation in bats and implications for a special viral reservoir host. Nat Microbiol. 2019;4(5):789-799. doi: https://doi.org/10.1038/s41564-019-0371-3De Francesco EM, Vella V, Belfiore A. COVID-19 and diabetes: the importance of controlling RAGE. Front. Endocrinol. 2020;(11):526. doi: https://doi.org/10.3389/fendo.2020.00526De Francesco EM, Vella V, Belfiore A. COVID-19 and diabetes: the importance of controlling RAGE. Front. Endocrinol. 2020;(11):526. doi: https://doi.org/10.3389/fendo.2020.00526Lechleitner M, Koch T, Herold M, et al. Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. J Intern Med. 2000;248(1):67-76. doi: https://doi.org/10.1046/j.1365-2796.2000.00705.xLechleitner M, Koch T, Herold M, et al. Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. J Intern Med. 2000;248(1):67-76. doi: https://doi.org/10.1046/j.1365-2796.2000.00705.xPickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40(11):1286-1292. doi: https://doi.org/10.1007/s001250050822Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40(11):1286-1292. doi: https://doi.org/10.1007/s001250050822Bode B, Garrett V, Messler J, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020;14(4):813-821. doi: https://doi.org/10.1177/1932296820924469Bode B, Garrett V, Messler J, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020;14(4):813-821. doi: https://doi.org/10.1177/1932296820924469Hudson BI, Lippman ME. Targeting RAGE Signaling in Inflammatory Disease. Annu Rev Med. 2018;69(1):349-364. doi: https://doi.org/10.1146/annurev-med-041316-085215Hudson BI, Lippman ME. Targeting RAGE Signaling in Inflammatory Disease. Annu Rev Med. 2018;69(1):349-364. doi: https://doi.org/10.1146/annurev-med-041316-085215Suresh R, Mosser DM. Pattern recognition receptors in innate immunity, host defense, and immunopathology. Adv Physiol Educ. 2013;37(4):284-291. doi: https://doi.org/10.1152/advan.00058.2013Suresh R, Mosser DM. Pattern recognition receptors in innate immunity, host defense, and immunopathology. Adv Physiol Educ. 2013;37(4):284-291. doi: https://doi.org/10.1152/advan.00058.2013Sirois CM, Jin T, Miller AL, et al. RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA. J Exp Med. 2013;210(11):2447-2463. doi: https://doi.org/10.1084/jem.20120201Sirois CM, Jin T, Miller AL, et al. RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA. J Exp Med. 2013;210(11):2447-2463. doi: https://doi.org/10.1084/jem.20120201Andersson U, Yang H, Harris H. High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells. Semin Immunol. 2018;38(11):40-48. doi: https://doi.org/10.1016/j.smim.2018.02.011Andersson U, Yang H, Harris H. High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells. Semin Immunol. 2018;38(11):40-48. doi: https://doi.org/10.1016/j.smim.2018.02.011Boteanu RM, Uyy E, Suica VI, Antohe F. High-mobility group box 1 enhances the inflammatory process in diabetic lung. Arch Biochem Biophys. 2015;583(11):55-64. doi: https://doi.org/10.1016/j.abb.2015.07.020Boteanu RM, Uyy E, Suica VI, Antohe F. High-mobility group box 1 enhances the inflammatory process in diabetic lung. Arch Biochem Biophys. 2015;583(11):55-64. doi: https://doi.org/10.1016/j.abb.2015.07.020Kim EJ, Park SY, Baek SE, et al. HMGB1 increases IL-1β production in vascular smooth muscle cells via NLRP3 inflammasome. Front Physiol. 2018;9(11):55-64. doi: https://doi.org/10.3389/fphys.2018.00313Kim EJ, Park SY, Baek SE, et al. HMGB1 increases IL-1β production in vascular smooth muscle cells via NLRP3 inflammasome. Front Physiol. 2018;9(11):55-64. doi: https://doi.org/10.3389/fphys.2018.00313Uchida T, Shirasawa M, Ware LB, et al. Receptor for advanced glycation end-products is a marker of type i cell injury in acute lung injury. Am J Respir Crit Care Med. 2006;173(9):1008-1015. doi: https://doi.org/10.1164/rccm.200509-1477OCUchida T, Shirasawa M, Ware LB, et al. Receptor for advanced glycation end-products is a marker of type i cell injury in acute lung injury. Am J Respir Crit Care Med. 2006;173(9):1008-1015. doi: https://doi.org/10.1164/rccm.200509-1477OCWu H, Li R, Pei L-G, et al. Emerging role of high mobility group box-1 in thrombosis-related diseases. Cell Physiol Biochem. 2018;47(4):1319-1337. doi: https://doi.org/10.1159/000490818Wu H, Li R, Pei L-G, et al. Emerging role of high mobility group box-1 in thrombosis-related diseases. Cell Physiol Biochem. 2018;47(4):1319-1337. doi: https://doi.org/10.1159/000490818Vogel S, Bodenstein R, Chen Q, et al. Platelet-derived HMGB1 is a critical mediator of thrombosis. J Clin Invest. 2015;125(12):4638-4654. doi: https://doi.org/10.1172/JCI81660Vogel S, Bodenstein R, Chen Q, et al. Platelet-derived HMGB1 is a critical mediator of thrombosis. J Clin Invest. 2015;125(12):4638-4654. doi: https://doi.org/10.1172/JCI81660Hoste E, Maueröder C, van Hove L, et al. Epithelial HMGB1 delays skin wound healing and drives tumor initiation by priming neutrophils for NET formation. Cell Rep. 2019;29(9):2689-2701.e4. doi: https://doi.org/10.1016/j.celrep.2019.10.104Hoste E, Maueröder C, van Hove L, et al. Epithelial HMGB1 delays skin wound healing and drives tumor initiation by priming neutrophils for NET formation. Cell Rep. 2019;29(9):2689-2701.e4. doi: https://doi.org/10.1016/j.celrep.2019.10.104Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;43(7):1408-1415. doi: https://doi.org/10.1172/jci.insight.138999Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;43(7):1408-1415. doi: https://doi.org/10.1172/jci.insight.138999Whittall-García LP, Torres-Ruiz J, Zentella-Dehesa A, et al. Neutrophil extracellular traps are a source of extracellular HMGB1 in lupus nephritis: associations with clinical and histopathological features. Lupus. 2019;28(13):1549-1557. doi: https://doi.org/10.1177/0961203319883936Whittall-García LP, Torres-Ruiz J, Zentella-Dehesa A, et al. Neutrophil extracellular traps are a source of extracellular HMGB1 in lupus nephritis: associations with clinical and histopathological features. Lupus. 2019;28(13):1549-1557. doi: https://doi.org/10.1177/0961203319883936Jeong J, Lee J, Lim J, et al. Soluble RAGE attenuates AngII-induced endothelial hyperpermeability by disrupting HMGB1-mediated crosstalk between AT1R and RAGE. Exp Mol Med. 2019;51(9):1-15. doi: https://doi.org/10.1038/s12276-019-0312-5Jeong J, Lee J, Lim J, et al. Soluble RAGE attenuates AngII-induced endothelial hyperpermeability by disrupting HMGB1-mediated crosstalk between AT1R and RAGE. Exp Mol Med. 2019;51(9):1-15. doi: https://doi.org/10.1038/s12276-019-0312-5Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-1418. doi: https://doi.org/10.1016/S0140-6736(20)30937-5Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-1418. doi: https://doi.org/10.1016/S0140-6736(20)30937-5Bermejo-Martin J, Martín-Fernandez M, López-Mestanza C, et al. Shared features of endothelial dysfunction between sepsis and its preceding risk factors (aging and chronic disease). J Clin Med. 2018;7(11):400. doi: https://doi.org/10.3390/jcm7110400Bermejo-Martin J, Martín-Fernandez M, López-Mestanza C, et al. Shared features of endothelial dysfunction between sepsis and its preceding risk factors (aging and chronic disease). J Clin Med. 2018;7(11):400. doi: https://doi.org/10.3390/jcm7110400Wang K, Chen W, Zhou YS, et al. SARSCoV-2 invades host cells via a novel route: CD147-spike protein. bioRxiv. 2020. doi: https://doi.org/10.1101/2020.03.14.988345Wang K, Chen W, Zhou YS, et al. SARSCoV-2 invades host cells via a novel route: CD147-spike protein. bioRxiv. 2020. doi: https://doi.org/10.1101/2020.03.14.988345Heinzmann D, Noethel M, von Ungern-Sternberg S, et al. CD147 is a novel interaction partner of integrin αMβ2 mediating leukocyte and platelet adhesion. Biomolecules. 2020;10(4):541. doi: https://doi.org/10.3390/biom10040541Heinzmann D, Noethel M, von Ungern-Sternberg S, et al. CD147 is a novel interaction partner of integrin αMβ2 mediating leukocyte and platelet adhesion. Biomolecules. 2020;10(4):541. doi: https://doi.org/10.3390/biom10040541Sardu C, D’Onofrio N, Balestrieri ML, et al. Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control? Diabetes Care. 2020;43(7):1408-1415. doi: https://doi.org/10.2337/dc20-0723Sardu C, D’Onofrio N, Balestrieri ML, et al. Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control? Diabetes Care. 2020;43(7):1408-1415. doi: https://doi.org/10.2337/dc20-0723Arabi YM, Dehbi M, Rishu AH, et al. sRAGE in diabetic and non-diabetic critically ill patients: effects of intensive insulin therapy. Crit Care. 2011;15(4):R203. doi: https://doi.org/10.1186/cc10420Arabi YM, Dehbi M, Rishu AH, et al. sRAGE in diabetic and non-diabetic critically ill patients: effects of intensive insulin therapy. Crit Care. 2011;15(4):R203. doi: https://doi.org/10.1186/cc10420Ingels C, Derese I, Wouters PJ, et al. Soluble RAGE and the RAGE ligands HMGB1 and S100A12 in critical illness. Shock. 2015;43(2):109-116. doi: https://doi.org/10.1097/SHK.0000000000000278Ingels C, Derese I, Wouters PJ, et al. Soluble RAGE and the RAGE ligands HMGB1 and S100A12 in critical illness. Shock. 2015;43(2):109-116. doi: https://doi.org/10.1097/SHK.0000000000000278Mi L, Zhang Y, Xu Y, et al. HMGB1/RAGE pro-inflammatory axis promotes vascular endothelial cell apoptosis in limb ischemia/reperfusion injury. Biomed Pharmacother. 2019;116(2):109005. doi: https://doi.org/10.1016/j.biopha.2019.109005Mi L, Zhang Y, Xu Y, et al. HMGB1/RAGE pro-inflammatory axis promotes vascular endothelial cell apoptosis in limb ischemia/reperfusion injury. Biomed Pharmacother. 2019;116(2):109005. doi: https://doi.org/10.1016/j.biopha.2019.109005Rao NV, Argyle B, Xu X, et al. Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands. Am J Physiol Physiol. 2010;299(1):C97-C110. doi: https://doi.org/10.1152/ajpcell.00009.2010Rao NV, Argyle B, Xu X, et al. Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands. Am J Physiol Physiol. 2010;299(1):C97-C110. doi: https://doi.org/10.1152/ajpcell.00009.2010Ding J, Cui X, Liu Q. Emerging role of HMGB1 in lung diseases: friend or foe. J Cell Mol Med. 2017;21(6):1046-1057. doi: https://doi.org/10.1111/jcmm.13048Ding J, Cui X, Liu Q. Emerging role of HMGB1 in lung diseases: friend or foe. J Cell Mol Med. 2017;21(6):1046-1057. doi: https://doi.org/10.1111/jcmm.13048Takahashi Y, Matsutani N, Dejima H, et al. Therapeutic potential of recombinant thrombomodulin for lung injury after pneumonectomy via inhibition of high-mobility group box 1 in mice. J Trauma Acute Care Surg. 2016;81(5):868-875. doi: https://doi.org/10.1097/TA.0000000000001208Takahashi Y, Matsutani N, Dejima H, et al. Therapeutic potential of recombinant thrombomodulin for lung injury after pneumonectomy via inhibition of high-mobility group box 1 in mice. J Trauma Acute Care Surg. 2016;81(5):868-875. doi: https://doi.org/10.1097/TA.0000000000001208Valeriani E, Squizzato A, Gallo A, et al. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy: a systematic review and meta-analysis. J Thromb Haemost JTH. 2020;18(7):1618-1625. doi: https://doi.org/10.1111/jth.14812Valeriani E, Squizzato A, Gallo A, et al. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy: a systematic review and meta-analysis. J Thromb Haemost JTH. 2020;18(7):1618-1625. doi: https://doi.org/10.1111/jth.14812Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181(4):905-913.e7. doi: https://doi.org/10.1016/j.cell.2020.04.004Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181(4):905-913.e7. doi: https://doi.org/10.1016/j.cell.2020.04.004

The authors declare that there are no conflicts of interest present.